Live
BioPharma DiveCytospire hauls in $83M for a new type of T cell engagerSamsung BiologicsSamsung Biologics Labor Talks Break Down, Gap Remains - thelec.netSiemens HealthineersCDC HoSt-TT certification for Siemens Healthineers total testosterone test expands patient access to gold standard equivalent results - News-MedicalSamsung BiologicsSamsung Biologics union continues first general strike, demands higher wages and performance-based pay - Korea JoongAng DailyFierceBiotechPrivate Swiss biotechs hit record funding amid slowdown in public financingSamsung BiologicsSamsung Biologics' strike enters 5th day - Yonhap News AgencyeLifeAre kinocilia motile?eLifeHuman adherent cortical organoids in a multi-well formatEndpoints NewsVertex drops mRNA cystic fibrosis program over 'tolerability' issuesBio-RadBio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab ManagerFierceBiotechVertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues
FierceBiotech Mar 20, 2026

Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle

Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle

Original
Body unavailable. Use the original source.